Systemic and glomerular hypertension and progression of chronic renal disease: The dilemma of nephrosclerosis

Kidney International

Volumn 68, Issue SUPPL. 99, 2005, Pages

  Marín, Rafael ^a   Gorostidi, Manuel ^b   Fernández Vega, Francisco ^b   Álvarez Navascués, Rafael ^b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b NONE

Author keywords

Hypertension; Hypertensive nephropathy; Nephrosclerosis

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; GLOMERULUS; HUMAN; KIDNEY BLOOD VESSEL; KIDNEY FAILURE; MICROVASCULATURE; NEPHROSCLEROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; ETHNOLOGY; FEMALE; HYPERTENSION; KIDNEY DISEASE; MALE; PATHOPHYSIOLOGY; RENOVASCULAR HYPERTENSION; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; NEPHROSCLEROSIS; PROGNOSIS;

EID: 33748329386     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09910.x     Document Type: Conference Paper

References (38)

1. GUYTON AC, COLEMAN TG, COWLEY AV Jr, et al: Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52:584-594, 1972
2. SARNAK JA, GREENE T, WANG X, et al: The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142:342-351, 2005
3. MASCHIO G, ALBERTI D, JANIN G, et al: Effect of the angiotensin- converting-enzyme inhibitor on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
4. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43(Suppl 1):S1-S290, 2004
5. HSU CY: Does non-malignant hypertension cause renal insufficiency? Evidence-based perspective. Curr Opin Nephrol Hypertens 11:267-272, 2002
6. MARÍN R, GOROSTIDI M, POBES A: Hipertensión arterial y enfermedad vascular renal: nefroangioesclerosis. Nefrología 22(Suppl 1):S36-S45, 2002
7. FREEDMAN BI, ISKANDAR SS, APPEL RG: The link between hypertension and nephrosclerosis. Am J Kidney Dis 25:207-221, 1995
8. BLEYER AJ, APPEL RG: Risk factors associated with hypertensive nephrosclerosis. Nephron 82:193-198, 1999
9. WEISSTUCH JM, DWORKIN LD: Does essential hypertension cause end-stage renal disease? Kidney Int 41(Suppl 36):S33-S37, 1992
10. LUKE RG: Essential hypertension: A renal disease? Hypertension 21:380-390, 1993
11. LUFT FC: Hypertensive nephrosclerosis: Update. Curr Opin Nephrol Hypertens 13:147-154, 2004
12. ZARIF L, COVIC A, IYENGAR S, et al: Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 15:1801-1807, 2000
13. SHULMAN NB, FORD CE, HALL WD, et al, ON BEHALF OF HYPERTENSION DETECTION AND FOLLOW-UP PROGRAM COOPERATIVE GROUP: Prognostic value of serum creatinine and the effect of treatment of hypertension on renal function. Hypertension 13(Suppl 11):S80-S93, 1989
14. PERNEGER TV, NIETO J, WHELTON PC, et al: A prospective study of blood pressure and serum creatinine: Results for the "Clue" study and the Atherosclerosis Risk in Communities study. JAMA 269:488-493, 1993
15. PERRY HM, MILLER JP, FORNOFF JR, et al: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25:587-594, 1995
16. KLAG MJ, WHELTON PK, RANDALL BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996
17. SIEWERT-DELLE A, LJUNGMAN S, ANDERSSON OK, WILHELMSEN L: Does treated primary hypertension lead to end-stage renal disease? A 20-year follow-up of the Primary Prevention Study in Göteborg, Sweden. Nephrol Dial Transplant 13:3084-3090, 1998
18. YOUNG JH, KLAG MJ, MUNTNER P, et al: Blood pressure and decline in kidney function: Findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol 13:2776-2782, 2002
19. TOZAWA M, ISEKI K, ISEKI C, et al: Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 41:1341-1345, 2003
20. VUPPUTURI S, BATUMAN V, MUNTNER P, et al: Effect of blood pressure on early decline in kidney function among hypertensive men. Hypertension 42:1144-1149, 2003
21. SEGURA J, CAMPO C, GIL P, et al: Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 15:1616-1622, 2004
22. HSU CY, MCCULLOCH CE, DARBINIAN J, et al: Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 165:923-928, 2005
23. TOMSON CRV, PETERSEN K, HEAGERTY AM: Does treated essential hypertension result in renal impairment? A cohort study. J Hum Hypertens 5:189-192, 1991
24. ISEKI K, IKEMIYA Y, FUKIYAMA K: Blood pressure and risk of end-stage renal disease in a screened cohort. Kidney Int 49(Suppl 55):S69-S71, 1996
25. LJUNGMAN S: The kidney as a target of hypertension. Curr Hypertens Rep 1:164-169, 1999
26. AGODOA LY, APPEL L, BAKRIS GL, et al, FOR THE AFRICAN AMERICAN STUDY OF KIDNEY DISEASE AND HYPERTENSION STUDY GROUP: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomised controlled trial. JAMA 285:2719-2728, 2001
27. HSU CY: Does treatment of non-malignant hypertension reduce the incidence of renal dysfunction? A meta-analysis of 10 randomized, controlled trials. J Hum Hypertens 15:81-84, 2001
28. TRACY ER, STRONG JP,NEWMAN WP III, et al: Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25 to 54 years. Kidney Int 49:564-570, 1996
29. KELLER G, ZIMMER G, MAIL G, et al: Nephron number in patients with primary hypertension. N Engl J Med 348:101-108, 2003
30. ZUCCHELLI P, ZUCCALÀ A: Progression of renal failure and hypertensive nephrosclerosis. Kidney Int 54(Suppl 68):S55-S59, 1998
31. TOTO RB: Hypertensive nephrosclerosis in African Americans. Kidney Int 64:2331-2341, 2003
32. VIKSE BE, AASARØD K, BOSTAD L, IVERSEN BM: Clinical prognostic factors in biopsy-proven benign nephrosclerosis. Nephrol Dial Transplant 18:517-523, 2003
33. MARCANTONI C, MA L-J, FEDERSPIEL C, FOGO AB: Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int 62:172-180, 2002
34. WRIGHT JR, DUGGAL A, THOMAS R, et al: Clinicopathological correlation in biopsy-proven atherosclerotic nephropathy: Implications for renal functional outcome in atherosclerotic renovascular disease. Nephrol Dial Transplant 16:765-770, 2001
35. LEVIN A, DJURDJEV O, BARRETT B, et al: Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am J Kidney Dis 38: 1398-1407, 2001
36. MCCLELLAN WM, LANGSTON RD, PRESLEY R: Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 15:1912-1919, 2004
37. WRIGHT JT, BAKRIS G, GREENE T, et al, FOR THE AFRICAN AMERICAN STUDY OF KIDNEY DISEASE AND HYPERTENSION STUDY GROUP: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 288:2421-2431, 2002
38. SEGURA J, CAMPO C, RODICIO JL, RUILOPE LM: ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. Hypertension 38:645-649, 2001